Nasdaq
$433.70▲ 0.04%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $10.00BShares out 23.1M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
14- 9.28After-hours26.09.29 05:19144Ownership#●●●#●●●
MADRIGAL PHARMACEUTICALS, INC.
Madrigal Pharmaceuticals (MDGL) insider Paul A. Friedman has filed an SEC Form 144 to report a proposed sale of company shares. This is a standard regulatory filing indicating the insider's plan to dispose of their holdings.…more
$433.70+0.04%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.11After-hours26.09.12 05:574Ownership
MADRIGAL PHARMACEUTICALS, INC.
William John Sibold, an executive at Madrigal Pharmaceuticals, Inc., reported a change in beneficial ownership of company securities on September 9, 2026. This filing serves as an official disclosure of the insider's transaction to the SEC.…more
$433.70+0.04%vs prev closeView filingShare - 9.11After-hours26.09.12 05:33144Ownership
MADRIGAL PHARMACEUTICALS, INC.
William John Sibold, an insider at Madrigal Pharmaceuticals (MDGL), has filed a Form 144 to report the proposed sale of company shares. This is a standard regulatory filing indicating an insider's plan to dispose of their holdings.…more
$433.70+0.04%vs prev closeView filingShare
13 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.15After-hours26.10.16 05:05#●●●
Madrigal Pharmaceuticals Grants Equity Inducement Awards to New Employees…more
Madrigal Pharmaceuticals has granted restricted stock units to 26 new non-executive employees as an inducement for their hiring. This is a standard corporate practice for talent acquisition and does not have a significant immediate financial impact.…more
$433.70+0.04%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.6Pre-market26.10.06 21:14
●●●●●●●● ●●●●● ●●●●●●
Madrigal Pharmaceuticals published a secondary analysis of its Phase 3 MAESTRO-NASH trial in the Journal of Hepatology. The study evaluated how genetic risk variants influence patient response to Rezdiffra, though it does not provide immediate financial impact.…more
$433.70+0.04%vs prev closeShareBenzinga - 9.16After-hours26.09.17 05:05
●●●●●●●● ●●●●● ●●●●●●
Madrigal Pharmaceuticals has granted stock options and restricted stock units to 27 new non-executive employees as an inducement for their employment. This is a standard corporate practice for talent acquisition and does not significantly impact the company's financial standing.…more
$433.70+0.04%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report